Tirzepatide and GLP-1 studies found less hunger, lower weight, and lower blood sugar

Tirzepatide cut hunger, weight, and blood sugar

Many people first noticed less hunger. Tirzepatide copies two hormones that come from the gut, including GLP-1, which help manage hunger and blood sugar ^[1].

The diabetes research included 10 phase 3 studies, the last large test stage. More than 13,000 adults with type 2 diabetes joined them ^[2][3][4].

Other work examined sleep apnea and heart failure, plus excess weight and liver illness ^[5][6][7][8]. At 15 mg, average weight fell from 16 to 22.5%, and average blood sugar fell too ^[2][5].

The numbers come from published studies and the FDA drug record. I'd ask what the closest study means for you and when your doctor would check your progress.

One weekly shot kept tirzepatide in the blood

Tirzepatide is a protein drug with a 39-amino-acid chain based on one gut hormone, not GLP-1 ^[9]. Part 20 lets the drug hold onto a protein carried in your blood.

That link slows the drug's exit from the body ^[9]. Scientists list its tiny-particle weight as 4,813 daltons, a lab unit that doesn't guide your care.

About 80% of each shot reaches the blood. The blood level is highest 8 to 72 hours after a shot ^[10].

Tirzepatide copies GLP-1 and one more gut hormone ^[1]. Researchers know both affect hunger and blood sugar, but they can't say whether GLP-1 adds more help.

Read how tirzepatide works, or check the tirzepatide amounts used in studies.

Tirzepatide cut weight without raising heart risk

Weight fell most. SURMOUNT-1 followed 2,539 adults with excess weight but no diabetes for 72 weeks. At 15 mg, average weight fell 22.5%; with placebo, a shot without tirzepatide, it fell 2.4% ^[5].

At the two highest amounts, 96% lost at least 5% of their starting weight. That average loss was larger than any prior drug study had found.

Average blood sugar fell. In SURPASS-1, the blood test improved at 5 mg through 15 mg over 40 weeks. With tirzepatide, 81–86% reached 6.5% or less, while the test rose with placebo ^[2].

SURPASS-4 tracked adults likely to have heart trouble. At 15 mg, average blood sugar dropped farther than with insulin glargine, a long-lasting insulin shot ^[4].

Three grave heart risks didn't rise. SURPASS-CVOT followed 13,299 adults with type 2 diabetes and clogged arteries for 4 years. Heart death, heart attack, and stroke were about as common with tirzepatide as with dulaglutide, a GLP-1 drug ^[19].

The study showed tirzepatide didn't raise those three risks. Death from any cause was 16% lower, yet that result alone can't prove heart protection.

The study groups may not match your health. The full tirzepatide study results name who took part, what changed, and what to ask at your visit.

Tirzepatide copies two hormones from your gut

Tirzepatide has a 39-amino-acid chain of linked protein parts and copies two gut hormones, including GLP-1 ^[1][9]. The studies enrolled people with type 2 diabetes or excess weight.

The FDA cleared tirzepatide for type 2 diabetes in May 2022. It added long-term weight care for certain adults in November 2023.

GLP-1 affects hunger and blood sugar. Together, the two copied hormones may quiet hunger and help your body use stored fat ^[21][22].

Tirzepatide also helped some liver, heart, and sleep problems

The cleared uses are type 2 diabetes and long-term weight care for some adults. Separate studies examined illnesses often linked with excess weight.

After 52 weeks, people with severe fatty liver illness had less swelling and damage ^[16]. A heart study found 46% fewer heart deaths or bouts of worse heart failure ^[17].

People with severe sleep apnea had 25–29 fewer pauses in breathing each hour ^[18]. Ask whether any study included someone with health like yours.

A three-year SURMOUNT-1 study tracked adults with high blood sugar who didn't yet have diabetes. Tirzepatide cut their move to type 2 diabetes by 94% versus placebo ^[20].

Tirzepatide copies GLP-1 and another gut hormone

Tirzepatide copies GLP-1, a gut hormone used by many weight drugs ^[1]. The drug also copies a second hormone tied to blood sugar.

Together, GLP-1 and the second hormone may curb hunger, release insulin, and help your body use fat. Those are the useful jobs to know.

Researchers think GLP-1 may ease nausea caused by the second hormone. They haven't proved that idea, so read the GLP-1 hormone findings with care.

Tirzepatide helped people feel full sooner

Tirzepatide copies GLP-1, a gut hormone that can help you feel full sooner ^[21][22]. Food also left the stomach more slowly at first, and the body may have used stored fat.

GLP-1 and the second copied hormone reach brain areas that control hunger ^[22]. That may explain why people kept eating less after their stomachs sped up again.

In SURMOUNT-1, people taking 15 mg lost an average 22.5% by 72 weeks ^[5]. Their loss came near results once linked mostly with surgery.